Skip To Main Content

Monitoring disease progression

Think Fabry, think regular profile-based assessments.

The following assessments enable you to evaluate your patients on a regular basis. In addition to monitoring GL-3 and lyso-GL-3, this guidance considers other important factors that can help you monitor the progression of Fabry disease.1-6

These assessments are based on published guidelines and recommendations developed by the Fabry Registry Board of Advisors, a group of physicians who have experience in managing patients with Fabry disease. The Fabry Registry is sponsored by Sanofi.3-7

The Recommended Schedule of Assessments represents the core Fabry disease—related assessments that allow evaluation of a patient’s disease progression over time. Physicians will determine the actual frequency of necessary assessments according to a patient’s individualized need for medical care and routine follow-up. Assessments appropriate to individual patients may vary depending upon the clinical judgment of the treating physician, and the patient's need.

Disease-related assessments for patients ≥18 years of age1,7

Disease-related_Assessments_Patients_GreaterThan_18-years-of-age_Chart2
Safety

Relaterade Artiklar

MAT-BE-2500570 (ver. 1) 05/2025